Canada is witnessing a notable decline in opioid prescriptions, a trend that could signal meaningful shifts in healthcare practices — but here's where it gets controversial... Despite ongoing shortages of widely used pain medications like Tylenol 3 and Percocet, fewer Canadians are now being prescribed opioids. This reduction in prescribing habits is seen by many experts as a cautious move by doctors aiming to minimize harm. As Jennifer Lake, a pharmacy professor at the University of Toronto, explained via email to Canadian Affairs, this approach reflects a deliberate effort focused on 'deprescribing,' which involves reducing unnecessary medication use to prevent potential negative outcomes.
However, not everyone views these shortages positively. Contrarily, Jaris Swidrovich, another pharmacy expert from the same university, cautions that shortages of painkillers—whether caused by supply issues or other factors—are not good news. He emphasizes that medications are prescribed for very specific reasons, particularly for patients with severe, chronic, or terminal conditions, where opioids help maintain quality of life.
A Long-Standing Crisis with Roots in the Past
Canada’s struggle with opioid misuse and addiction stretches back to the late 1990s. During that period, overzealous prescribing practices—often driven by a misguided belief that opioids were safe—laid the groundwork for a widespread epidemic of addiction. As it became evident just how addictive these drugs are, doctors responded by tightening their prescribing practices. Unfortunately, this created a gap in pain management, which illicit drug traffickers, especially those peddling fentanyl, scrambled to fill. Fentanyl—a powerful synthetic opioid—has caused many fatalities, with approximately 54,000 Canadians dying from overdose-related causes over the last decade. Sadly, opioid overdoses continue to take about 18 lives each day.
Recent research published on October 27 in the Canadian Medical Association Journal indicates that this ongoing crisis might be influencing doctors to further curtail opioid prescriptions. The study tracked prescription patterns across six Canadian provinces—British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Quebec—between 2018 and 2022. Results showed a nearly 8% drop in the number of new patients starting opioid therapy and an over 11% decrease in current users. While data from some regions like the Atlantic provinces and territories were unavailable, the overall trend aligned with national efforts to promote safer and more appropriate opioid prescribing, especially for pain not related to cancer.
A Shift in Prescriber Attitudes and Strategies
David Juurlink, an internist and expert in pharmacology and toxicology at Toronto’s Sunnybrook Health Sciences Centre, comments that the perception of opioid safety remains a major stumbling block. In his view, doctors have long overused opioids as a default solution for managing pain, despite evidence that these medications are most effective in the early days of treatment, at low doses, and when combined with other pain management techniques.
Today, many Canadian physicians prefer to start with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen, which generally carry fewer risks of addiction or dependence. Juurlink notes that these changes represent a significant move away from the peak prescribing practices around 2010—highlighting a broader shift towards safer, more mindful pain management approaches.
Opportunities and Challenges Amid Medication Shortages
The recent disruptions in the supply of opioids—stemming from manufacturing issues—have unintentionally prompted healthcare providers to rethink their prescribing habits once again. Lake, from the University of Toronto, explains that this shortage, which began in the summer, offers a critical opportunity for clinicians to reassess individual patient needs, possibly reducing doses or exploring alternative therapies.
The shortage hit chronic pain patients particularly hard, especially those relying daily on medications like Tylenol 3 or Percocet. Lake suggests that this situation could serve as a catalyst for moving patients toward longer-acting or lower-dose options that provide effective pain relief with fewer pills. She emphasizes that chronic pain is often variable—meaning it can lessen over time—and that some patients might find their pain improving, thus lessening their dependence on medication.
But Not Everyone Sees It That Way
Despite these potential benefits, some experts, like Swidrovich, remain cautious. He insists that many patients still depend heavily on opioids for their daily comfort and functional independence. For individuals battling severe or chronic conditions, abrupt removal or rationing of these medications could cause suffering or hinder their quality of life.
Swidrovich points out that medication regimens are meant to evolve alongside the patient’s changing condition. That means opioids will continue to be an integral part of pain management for some, especially in cases of terminal illness or severe post-surgical pain. He remains hopeful, however, that prescribing practices will prioritize patient-centered care guided by the latest, evidence-based standards—rather than influenced solely by supply issues.
So, where do you stand? Is decreasing opioid use a vital step toward combating addiction, or are we risking unintended suffering by limiting access to necessary pain relief? Share your thoughts below—should supply shortages prompt more cautious prescribing, or do we need to ensure those in real need are not caught in the crossfire?
